In this episode, we will discuss clinical trial results that served as the basis for the FDA's approval of teplizumab as the first immunotherapy for delaying type 1 diabetes mellitus.
Each month, APhA will release five, 5-minute podcast episodes offering a fresh dose of education highlights, practice pearls, and insights to inform your pharmacy practice and advance patient care. Listen at your convenience! Both members and nonmembers can log into their APhA pharmacist.com Learning Library account to successfully complete a short assessment at the end of each month to earn 0.5 hours of CE credits (.05 CEU). The first inaugural first six are free! Tune in now on our website or subscribe via Google, Spotify, or Apple Podcasts.
The American Pharmacists Association is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing education.
Disclaimer: The content is intended for informational purposes only and should not be considered or taken as medical advice. The views and opinions expressed in this program are those of the speakers and do not necessarily reflect the opinions or positions of any entities they represent or its employees.

Ver todos los episodios